Patriot Financial Group Insurance Agency LLC Acquires 8,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Patriot Financial Group Insurance Agency LLC increased its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 72.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,000 shares of the biopharmaceutical company’s stock after buying an additional 8,000 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Puma Biotechnology were worth $48,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of PBYI. SG Americas Securities LLC bought a new stake in shares of Puma Biotechnology during the first quarter valued at about $57,000. Victory Capital Management Inc. bought a new stake in Puma Biotechnology during the 2nd quarter worth approximately $54,000. The Manufacturers Life Insurance Company purchased a new stake in Puma Biotechnology in the 2nd quarter worth approximately $58,000. Lazard Asset Management LLC boosted its holdings in Puma Biotechnology by 5,129.0% in the 1st quarter. Lazard Asset Management LLC now owns 49,466 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 48,520 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Puma Biotechnology by 2,309.9% during the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 48,184 shares in the last quarter. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI opened at $2.84 on Thursday. The company’s fifty day moving average price is $2.61 and its 200-day moving average price is $3.42. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.32 and a quick ratio of 1.23. The firm has a market capitalization of $139.30 million, a price-to-earnings ratio of 15.05 and a beta of 1.09. Puma Biotechnology, Inc. has a one year low of $2.22 and a one year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. The business had revenue of $47.10 million for the quarter, compared to analysts’ expectations of $43.99 million. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, equities research analysts anticipate that Puma Biotechnology, Inc. will post 0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PBYI. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, August 2nd. StockNews.com upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 23rd.

Insider Activity

In related news, Director Michael Patrick Miller sold 23,358 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now owns 47,000 shares in the company, valued at $164,030. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 23.70% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.